Last reviewed · How we verify
P2Y12
At a glance
| Generic name | P2Y12 |
|---|---|
| Also known as | Ticagrelor, Prasugrel, Clopidogrel |
| Sponsor | Matthew Neal MD |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent (PHASE4)
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (PHASE3)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion (PHASE4)
- Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P2Y12 CI brief — competitive landscape report
- P2Y12 updates RSS · CI watch RSS
- Matthew Neal MD portfolio CI